Holen Sie sich die Stockscreener-App
1.20
2.56%
0.03
Handel nachbörslich:
1.21
0.01
+0.83%
Schlusskurs vom Vortag:
$1.17
Offen:
$1.2
24-Stunden-Volumen:
1.20M
Relative Volume:
1.05
Marktkapitalisierung:
$94.53M
Einnahmen:
$5.03M
Nettoeinkommen (Verlust:
$-185.41M
KGV:
-0.3883
EPS:
-3.09
Netto-Cashflow:
$-139.79M
1W Leistung:
-13.04%
1M Leistung:
-16.67%
6M Leistung:
-90.96%
1J Leistung:
-88.68%
1-Tages-Spanne:
$1.16
$1.2499
1-Wochen-Bereich:
$1.13
$1.43
52-Wochen-Spanne:
$1.1001
$16.10
Pliant Therapeutics Inc Stock (PLRX) Company Profile
Firmenname
Pliant Therapeutics Inc
Sektor
Branche
Telefon
650-481-6770
Adresse
331 OYSTER POINT BOULEVARD, SOUTH SAN FRANCISCO, CA
Vergleichen Sie PLRX mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
PLRX
Pliant Therapeutics Inc
|
1.20 | 94.53M | 5.03M | -185.41M | -139.79M | -3.09 |
|
VRTX
Vertex Pharmaceuticals Inc
|
457.03 | 115.95B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
547.74 | 56.52B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
329.77 | 39.44B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
545.11 | 35.14B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
244.32 | 28.51B | 3.81B | -644.79M | -669.77M | -6.24 |
Pliant Therapeutics Inc Stock (PLRX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-03-04 | Fortgesetzt | Cantor Fitzgerald | Neutral |
| 2025-03-04 | Herabstufung | Needham | Buy → Hold |
| 2025-03-03 | Herabstufung | Leerink Partners | Outperform → Market Perform |
| 2025-03-03 | Herabstufung | Stifel | Buy → Hold |
| 2025-02-10 | Herabstufung | Canaccord Genuity | Buy → Hold |
| 2025-02-10 | Herabstufung | Citigroup | Buy → Neutral |
| 2025-02-10 | Herabstufung | H.C. Wainwright | Buy → Neutral |
| 2025-02-10 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2025-02-10 | Herabstufung | Oppenheimer | Outperform → Perform |
| 2025-02-10 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
| 2025-02-10 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2024-09-09 | Fortgesetzt | Leerink Partners | Outperform |
| 2023-12-08 | Eingeleitet | Wells Fargo | Overweight |
| 2023-05-18 | Eingeleitet | Canaccord Genuity | Buy |
| 2023-04-13 | Eingeleitet | Robert W. Baird | Outperform |
| 2022-12-14 | Eingeleitet | Stifel | Buy |
| 2022-12-07 | Eingeleitet | JP Morgan | Overweight |
| 2022-09-01 | Eingeleitet | Citigroup | Buy |
| 2022-07-20 | Eingeleitet | SVB Leerink | Outperform |
| 2022-05-25 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2021-12-10 | Eingeleitet | Oppenheimer | Outperform |
| 2021-11-24 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2021-11-03 | Eingeleitet | H.C. Wainwright | Buy |
| 2021-04-20 | Eingeleitet | BTIG Research | Buy |
| 2021-04-05 | Eingeleitet | Citigroup | Buy |
| 2020-06-29 | Eingeleitet | Citigroup | Buy |
| 2020-06-29 | Eingeleitet | Cowen | Outperform |
| 2020-06-29 | Eingeleitet | Needham | Buy |
| 2020-06-29 | Eingeleitet | Piper Sandler | Overweight |
Alle ansehen
Pliant Therapeutics Inc Aktie (PLRX) Neueste Nachrichten
Pliant Therapeutics Inc’s (PLRX) Stock Is Harder To Predict Than You Think - Stocksregister
Pliant Therapeutics amends corporate bylaws, holds stockholder vote By Investing.com - Investing.com Nigeria
Pliant Therapeutics amends corporate bylaws, holds stockholder vote - Investing.com
Pliant Therapeutics presents new fibrosis treatment data By Investing.com - Investing.com Canada
Pliant Therapeutics Presents Clinical and Preclinical Data at th - GuruFocus
Pliant Therapeutics presents new fibrosis treatment data - Investing.com
Pliant Therapeutics Presents Clinical and Preclinical Data at the American Thoracic Society International Conference | PLRX Stock News - GuruFocus
Pliant Therapeutics Presents Clinical and Preclinical Data at the American Thoracic Society ... - Eagle-Tribune
Pliant Therapeutics Presents Clinical and Preclinical Data at the American Thoracic Society International Conference - GlobeNewswire
How Are Things Looking For Pliant Therapeutics Inc (NASDAQ: PLRX) For The Short Term? - Stocksregister
Cautious Hold Rating on Pliant Therapeutics Amid Clinical and Financial Uncertainties - TipRanks
Another Bay Area biotech company announces layoffs - MSN
Pliant Therapeutics Reports Q1 2025 Financial Results - TipRanks
Pliant (PLRX) Prepares to Release Topline Results from BEACON-IP - GuruFocus
Pliant (PLRX) Prepares to Release Topline Results from BEACON-IPF Trial | PLRX Stock News - GuruFocus
Pliant Therapeutics reports Q1 EPS (92c), consensus (62c) - TipRanks
Pliant Therapeutics (PLRX) Advances in Clinical Trials and Oncology Research | PLRX Stock News - GuruFocus
Pliant Therapeutics Provides Corporate Update and Reports First Quarter 2025 Financial Results - GlobeNewswire
Market Watch Highlights: Pliant Therapeutics Inc (PLRX) Ends on an Downturn Note at 1.43 - DWinneX
Pliant Therapeutics Cuts Workforce by Nearly Half - Powder & Bulk Solids
Bay Area biotech company Pliant Therapeutics slashes staff after losing $655 million in value - MSN
Pliant cuts workforce by 45% following lung trial termination - Clinical Trials Arena
Pliant Therapeutics to cut 45% of workforce (PLRX:NASDAQ) - Seeking Alpha
Pliant Therapeutics (PLRX) Restructures to Prolong Financial Res - GuruFocus
Pliant Therapeutics Reduces Workforce as Part of Strategic Realignment - MarketWatch
Pliant Therapeutics (PLRX) Restructures to Prolong Financial Resources | PLRX Stock News - GuruFocus
Pliant Therapeutics announces workforce reduction By Investing.com - Investing.com India
Pliant Therapeutics announces workforce reduction - Investing.com
Pliant Therapeutics Announces Major Workforce Reduction - TipRanks
Pliant Therapeutics Announces Workforce Reduction and Cost Saving Initiatives to Support Late-Stage Clinical Trials - Nasdaq
Pliant Therapeutics Announces Strategic Realignment of Workforce and Operations - GlobeNewswire
Pliant Therapeutics Slashes Nearly Half its Workforce While Awaiting Crucial IPF Drug Results - Stock Titan
You might want to take a look at Pliant Therapeutics Inc (PLRX) now - Sete News
Pliant Therapeutics Inc [PLRX] stock was sold by Coulie Bernard at the price of US$0.59 million - knoxdaily.com
Market Momentum: Pliant Therapeutics Inc (PLRX) Registers a 0.68 Increase, Closing at 1.48 - DWinneX
Stock Performance Spotlight: Cg Oncology Inc (CGON) Ends the Day at 26.94, Down by -3.68 - DWinneX
Pliant Therapeutics Inc (PLRX)’s highs and lows: A closer look at its stock price fluctuations - uspostnews.com
Legal & General Group Plc Grows Stock Holdings in Pliant Therapeutics, Inc. (NASDAQ:PLRX) - Defense World
Pliant Therapeutics Inc: A Year of Highs, Lows, and Market Resilience - investchronicle.com
Press Release Distribution & PR Platform - ACCESS Newswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Pliant Therapeutics, Inc.PLRX - Louisiana First News
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Pliant ... - Bluefield Daily Telegraph
Pliant Therapeutics discovers new integrin αvβ1, αvβ6 and/or αvβ8 antagonists - BioWorld MedTech
Pliant Therapeutics Inc’s Market Journey: Closing Weak at 3.03, Down -1.62 - DWinneX
PLRXPliant Therapeutics, Inc. Latest Stock News & Market Updates - Stock Titan
Healthy Upside Potential: Pliant Therapeutics Inc (PLRX) - Sete News
Market Recap Check: Pliant Therapeutics Inc (PLRX)’s Positive Finish at 1.54, Up/Down 2.67 - DWinneX
Pliant Therapeutics Inc (PLRX)’s stock price in review: A technical analysis - uspostnews.com
Pliant Therapeutics, Inc. (NASDAQ:PLRX) Shares Bought by JPMorgan Chase & Co. - Defense World
Finanzdaten der Pliant Therapeutics Inc-Aktie (PLRX)
Umsatz
Nettogewinn
Free Cashflow
ENV
Pliant Therapeutics Inc-Aktie (PLRX) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Cummings Keith Lamont | Chief Financial Officer |
Jan 17 '25 |
Sale |
11.20 |
20,148 |
225,680 |
262,608 |
| Hull Hans | Chief Business Officer |
Jan 17 '25 |
Sale |
11.20 |
15,936 |
178,501 |
211,558 |
| Lefebvre Eric | Chief Medical Officer |
Jan 17 '25 |
Sale |
11.20 |
18,478 |
206,974 |
194,574 |
| Cheung Lily | Chief Human Resource Officer |
Jan 17 '25 |
Sale |
11.20 |
3,740 |
41,892 |
24,550 |
| Ouimette Mike | General Counsel & Corp. Sec'y |
Jan 17 '25 |
Sale |
11.20 |
13,270 |
148,639 |
80,774 |
| Ouimette Mike | General Counsel & Corp. Sec'y |
Jan 22 '25 |
Sale |
10.99 |
10,230 |
112,462 |
70,544 |
1.45%
0.86%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):